FDA Approves Ziftomenib, First-in-Class Targeted Therapy for NPM1-Mutated Acute Myeloid Leukemia
Key Insights
The FDA approved ziftomenib on November 13, 2025, as a targeted oral therapy for adults with relapsed or refractory acute myeloid leukemia carrying an NPM1 (search) mutation.
The approval was based on the pivotal KOMET-001 trial led by Roswell Park, where 23% of heavily pretreated patients achieved complete remission.
Ziftomenib represents a shift from traditional chemotherapy to precision medicine by targeting menin (search), a protein that fuels leukemia cell growth.
The U.S. Food and Drug Administration has approved ziftomenib, a first-in-class targeted therapy for adults with relapsed or refractory acute myeloid leukemia (AML) carrying an NPM1 (search) mutation. The approval, granted on November 13, 2025, marks a significant advancement in precision oncology for this aggressive blood cancer.
The approval is based on results from the pivotal phase 1/2 KOMET-001 trial, co-led globally by Dr. Eunice Wang, Chief of Leukemia at Roswell Park Comprehensive Cancer Center. The study findings were published in the Journal of Clinical Oncology in November, with Dr. Wang as first author.
Breakthrough Mechanism of Action
Ziftomenib works by blocking menin (search), a protein that fuels the growth of leukemia cells. This targeted approach represents a departure from traditional chemotherapy-based treatments that have dominated AML care. "We're moving away from just pouring more poisons into patients," Dr. Wang explained. "This drug targets the biology of the cancer itself."
The once-daily oral therapy offers a more precise treatment option for patients whose leukemia is driven by specific genetic mutations, moving the field toward personalized medicine approaches.
Clinical Trial Results
In the KOMET-001 study of 92 adults with relapsed or refractory AML carrying an NPM1 (search) mutation, all participants had received multiple lines of prior therapy. Despite this heavily pretreated population, 23% achieved a complete response with full count recovery, demonstrating no evidence of disease after treatment.
"Ziftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory AML," Dr. Wang and co-authors reported. The drug was well tolerated with a safety profile consistent with previous studies.
Some patients in the trial achieved complete remission even after failing as many as seven prior lines of treatment, highlighting the potential of this targeted approach in difficult-to-treat cases.
Patient Population and Clinical Impact
AML primarily affects older adults, with an average age at diagnosis of 70. Many patients develop the disease after previous cancer treatment or due to age-related genetic changes. Up to one-third of patients newly diagnosed with AML have the NPM1 (search) genetic subtype and could potentially be candidates for this treatment.
At Roswell Park alone, 30 to 40 patients have already received the drug, either as a standalone therapy or in combination with chemotherapy. The institution was the first in the world to treat patients with ziftomenib, with Dr. Wang noting, "The very first human being in the world to ever take this drug was treated here at Roswell Park."
Addressing Urgent Medical Need
When left untreated, aggressive AML can take a patient's life within days or weeks. Traditional AML treatment has relied heavily on chemotherapy that is broad, toxic, and not always effective, especially in older adults.
For patients who respond to ziftomenib, the drug provides not only remission but critically important time. This is particularly significant given the limited treatment options available for patients with relapsed or refractory disease.
Ongoing Development
Roswell Park continues to advance the development of ziftomenib through ongoing clinical trials investigating the agent in combination with chemotherapy in both newly diagnosed and relapsed/refractory settings. These studies aim to expand the therapeutic potential of this targeted approach across different patient populations and treatment scenarios.